Endocrinology

Obesity Medicine

Questions discussed in this category

When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?

How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?

Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...

1 Answer available

When do you consider using setmelanotide for treatment of hypothalamic obesity?

2 Answers available

Do you recommend non-bypass bariatric surgeries over intestinal bypass procedures for kidney transplant-eligible candidates to prevent oxalate nephropathy, given the higher risk of kidney oxalate deposition with intestinal bypass?

2 Answers available

What work up do you recommend in post bariatric surgery patients who are slowly gaining back the weight despite no changes in diet?

1 Answer available

How do you approach the use of GLP-1 receptor agonists for the management of patients with metabolically healthy obesity?

1 Answer available

Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?

3 Answers available

What strategies do you employ for adjusting the dosage of levothyroxine in hypothyroid patients who experience significant weight loss or are initiated on GLP-1 receptor agonists?

How often do you recommend monitoring thyroid function tests in these situations?

1 Answer available

How do you counsel patients on the use of compounded weight loss medications?

3 Answers available

Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?

3 Answers available

Should weight loss medications be used in women who are gaining excessive weight during pregnancy?

1 Answer available

Which patient population would benefit most from cellulose and citric acid (Plenity) therapy for weight loss?

1 Answer available

Should metformin be used in women with PCOS for weight loss?

1 Answer available

Papers discussed in this category

BMC endocrine disorders, 2024 Nov 18

Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.

International urology and nephrology, 2024 Nov 04

Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.

Cancers, 2024 Sep 22

Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.

Frontiers in pharmacology, 2023 Mar 16

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.

Nutrition & diabetes, 2019 Nov 04

Double or hybrid diabetes: A systematic review on disease prevalence, characteristics and risk factors.

Diabetes, obesity & metabolism, 2019 Aug 19

Double diabetes: A distinct high-risk group?

BMC endocrine disorders, 2021 Sep 16

The association between overweight/obesity and double diabetes in adults with type 1 diabetes; a cross-sectional study.

Diabetes care, 2021 May 05

High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study.

Kidney360, 2022 Aug 25

Bariatric Surgery Decreases Barriers for Kidney Transplant: Are There Other Weight-Loss Options?

Endocrinology

Obesity Medicine

Questions discussed in this category

Papers discussed in this category

Related Topics in Endocrinology